PRA Health Sciences, Inc. named a new member of the company’s board of directors, increasing the board to seven members, according to a filing with the Securities and Exchange Commission on Thursday.

The newest member of PRA Health Sciences’ board is Glen Stettin, M.D., the chief innovation officer at Express Scripts & Cigna Services, a division health insurance giant Cigna Corporation.

Stettin previously served as the chief innovation officer of Express Scripts before Cigna acquired the company in 2018. Before that, Stettin spent 17 years at Medco, holding leadership roles across clinical, operations, product and technology before the company sold to Express Scripts in 2012.

“We are delighted that Glen will be joining our board of directors. With his widespread involvement in the healthcare field as both a physician and an executive, Dr. Stettin’s experience in innovation, data, analytics, technology and integrated health solutions will provide the board with valuable insight as we continue to reinvent clinical research and make it more accessible to patients,” PRA’s CEO Colin Shannon said in a press release.

Stettin holds bachelor and medical degrees from Lehigh University and the Medical College of Pennsylvania.
.
Stettin joins the board as an independent Class I director effective Sept. 14 and is expected to stand for election during the company’s 2021 annual stockholder meeting, according to the filing.

PRA Health Sciences is a global contract research organization (CRO), which aids pharmaceutical companies by providing clinical studies and clinical trials for drugs and medical devices.

PRA shares (PRAH) were last seen trading down 1.06 percent, or $1.10, at $102.62.